文献速递流行病学与生物统计真实世界研究与卫生经济

加速监管审批背景下临床有效性评价的方法学挑战:一项综述

Methodological challenges for the evaluation of clinical effectiveness in the context of accelerated regulatory approval: an overview.
PubMed 文献 · J Clin Epidemiol · 2017-07-12

监管机构正基于有限证据批准创新疗法,虽足以判定风险获益平衡,但下游卫生技术评估需可靠的有效性估计以评估成本效果。本文通过务实文献综述考察非随机研究、小样本单臂试验、单中心试验及替代终点等方法学挑战,指出调整混杂的方法不完美、单臂试验相对疗效不确定且可能偏乐观、单中心结果可能不可推广、替代终点平均高估疗效,基于此类次优证据的有效性声明可能面临显著不确定性。

要点

  • 非随机研究调整混杂的方法不完美,单臂试验的相对疗效不确定且可能偏乐观。
  • 单中心试验结果可能不可推广,替代终点平均高估治疗效应。
  • 基于此类数据建模的成本效果评估可能面临显著不确定性,决策者不应低估该不确定性。

核心结论

  • 基于此类数据建模的成本效果评估可能面临显著不确定性,决策者不应低估该不确定性;需要量化不确定性的方法,并应实施保护支付方免受不确定性成本影响的方案。

研究设计与样本

  • 通过务实文献综述考察加速监管审批背景下临床有效性评价的方法学挑战。

主要发现

  • 非随机研究调整混杂的方法不完美。
  • 单臂试验产生的相对治疗效应不确定且可能偏乐观。
  • 单中心试验结果可能不可推广。
  • 替代终点平均高估治疗效应。
  • 分析此类数据的现有方法有限,基于这些次优证据形式的有效性声明可能面临显著不确定性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Regulatory authorities are approving innovative therapies with limited evidence. Although this level of data is sufficient for the regulator to establish an acceptable risk-benefit balance, it is problematic for downstream health technology assessment, where assessment of cost-effectiveness requires reliable estimates of effectiveness relative to existing clinical practice. Some key issues associated with a limited evidence base include using data, from nonrandomized studies, from small single-arm trials, or from single-center trials; and using surrogate end points. METHODS: We examined these methodological challenges through a pragmatic review of the available literature. RESULTS: Methods to adjust nonrandomized studies for confounding are imperfect. The relative treatment effect generated from single-arm trials is uncertain and may be optimistic. Single-center trial results may not be generalizable. Surrogate end points, on average, overestimate treatment effects. Current methods for analyzing such data are limited, and effectiveness claims based on these suboptimal forms of evidence are likely to be subject to significant uncertainty. CONCLUSION: Assessments of cost-effectiveness, based on the modeling of such data, are likely to be subject to considerable uncertainty. This uncertainty must not be underestimated by decision makers: methods for its quantification are required and schemes to protect payers from the cost of uncertainty should be implemented.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Woolacott N, Corbett M, Jones-Diette J, et al. Methodological challenges for the evaluation of clinical effectiveness in the context of accelerated regulatory approval: an overview. J Clin Epidemiol. 2017. PMID: 28709997. doi:10.1016/j.jclinepi.2017.07.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。